Microbial air sampling is critical to pharmaceutical environmental monitoring, yet no single method can confirm asepsis. With evolving expectations in EU GMP Annex 1:2022, manufacturers must combine surface, passive, and active air sampling to support sterility assurance. This paper examines the strengths and limitations of each approach, with a focus on active air sampling, collection efficiency, and the challenge of differentiating zero (0) versus one (1) CFU in Grade A environments, where continuous monitoring is now expected. Download the paper to learn how to optimize microbial air monitoring in critical cleanroom applications.
Microbial air samplers in pharmaceutical manufacturing facilities can be used via several methods:
Each method produces results based on microbial growth on agar media, though the instruments and sampling techniques vary.
As outlined in EU GMP Annex 1:2022, environmental and process monitoring are part of a broader Contamination Control Strategy (CCS), where viable, nonviable, and aseptic process simulation (APS) data must be evaluated together. No single monitoring element provides sufficient evidence on its own; instead, results are used collectively to confirm control effectiveness. (Learn more about Annex 1: 2022 here)
A key consideration across all methods is how well the sample reflects actual environmental conditions. In Grade A environments, where contamination levels are extremely low, sampling approaches must support reliable data interpretation over extended periods. While settle plates can extend exposure time, their qualitative nature limits their usefulness in highly controlled applications.
Sampling configuration, duration, and method selection all influence monitoring performance. Instruments such as the BioCaptĀ® Adjustable Height Microbial Air Sampler help optimize physical collection efficiency by accommodating different media heights and pour depths without compromising biological performance.
![]()